Codagenix, Inc., a clinical-stage synthetic biology company, is proud to announce the appointment of Kimber Poffenberger, Ph.D., as Chief Strategy Officer. Dr. Poffenberger will be responsible for driving the company’s growth and development of its innovative rational virus design platform for live-attenuated viral vaccines and immuno-oncology therapeutics.
Her expertise and strategic vision will be invaluable as Codagenix continues to advance its breakthrough technologies in the field of synthetic biology.
We are thrilled to have Kimber join Codagenix, where her remarkable experience in global vaccine development and her strategic acumen in leading cross-functional teams will be invaluable. Her deep regulatory and product knowledge will be instrumental in helping us bring our medicines to those in need.
J. Robert Coleman, Ph.D., M.B.A., Co-Founder and Chief Executive Officer of Codagenix, is confident that Kimber will be a tremendous asset as the company continues to advance its clinical pipeline of live attenuated vaccines and cancer virotherapeutics.
Dr. Poffenberger is thrilled to join the Codagenix team and contribute to their groundbreaking work in live attenuated virus design and development. Together, they will take on some of the most difficult challenges in infectious diseases, cancer and animal health.
He is eager to progress the Codagenix vaccine and oncology pipeline, which could potentially provide solutions to unmet needs for diseases such as RSV, influenza, breast cancer and COVID-19.
Dr. Poffenberger has an impressive 20+ years of experience in the pharmaceutical and biotechnology industries, ranging from discovery research to FDA review. She most recently worked as Principal Consultant at Poffenberger Regulatory Resources and was previously Senior Vice President, Head of Global Regulatory Affairs at Alvotech.
During her career, she has led successful vaccine product development teams from discovery to commercial life cycle management, including in her roles as Vice President and Regional US Head, Global Regulatory Affairs at GSK Vaccines and Executive Director, Global Vaccines Strategy at Merck.
Dr. Poffenberger also held positions at Intercell, MedImmune, and Iomai Corporation. She holds a Ph.D. in Microbiology from the University of Chicago, and a B.S. from Carnegie Mellon University.
About Codagenix, Inc.
Codagenix is revolutionizing the world of vaccines and viral therapeutics with its cutting-edge live-attenuated virus design and codon deoptimization platform. Founded on technology developed by National Academy of Science member Dr. Eckard Wimmer at Stony Brook University, Codagenix is supported by Adjuvant Capital, TopSpin Partners, and Euclidean Capital and has ongoing research and license programs with various federal agencies.
This groundbreaking platform has the potential to tackle some of our biggest threats in infectious disease, cancer, and animal health.